Literature DB >> 34993673

Maximum standardized uptake value change rate before and after neoadjuvant chemotherapy can predict early recurrence in patients with locally advanced esophageal cancer: a multi-institutional cohort study of 220 patients in Japan.

Kentaro Murakami1, Naoya Yoshida2, Yusuke Taniyama3, Kozue Takahashi3, Takeshi Toyozumi4, Takashi Uno5, Takashi Kamei3, Hideo Baba2, Hisahiro Matsubara4.   

Abstract

BACKGROUND: Neoadjuvant chemotherapy (NAC) followed by esophagectomy can improve the prognosis of locally advanced esophageal cancer (LAEC). However, LAEC reportedly recurred in 17-21% of patients within 6 months post surgery. Thus, current treatment strategies may be inadequate for LAECs with poor prognosis. Preoperative identification of patients with poor prognosis might aid in modification of treatment strategies. This study aimed to evaluate the usefulness of the maximum standardized uptake value change rate (ΔSUVmax) in predicting treatment effects on the primary lesion, prognosis, and LAEC recurrence.
METHODS: This study involved 220 esophageal cancer patients who underwent esophagectomy after NAC at three facilities in Japan. The optimal cut-off point for ΔSUVmax in predicting tumor regression grade (TRG) was calculated and used to assess the correlation between ΔSUVmax and postoperative survival.
RESULTS: The optimal cut-off point for ΔSUVmax was 0.5. The 5-year overall survival rate in patients with ΔSUVmax ≥ 0.5 was significantly higher than that in patients with ΔSUVmax < 0.5 (71.5% vs. 50.5%, P = 0.001). Multivariate analysis identified ΔSUVmax (hazards ratio, 0.496; P = 0.004) as an independent prognostic factor. Among 199 patients evaluated for recurrence, 24 (12.1%) showed recurrence within 6 months post surgery. Univariate analysis revealed ΔSUVmax as the only predictor for early recurrence (odds ratio, 0.222; P = 0.004).
CONCLUSION: ΔSUVmax before and after NAC is clinically useful as it could help predict TRG, survival outcome, and early recurrence within 6 months post esophagectomy and is easily obtainable in general clinical practice. We believe that it may also help determine suitable treatment strategies for LAEC.
© 2021. The Author(s) under exclusive licence to The Japan Esophageal Society.

Entities:  

Keywords:  Esophageal neoplasms; Esophagectomy; Neoadjuvant therapy; Positron emission tomography; Prognosis

Mesh:

Substances:

Year:  2022        PMID: 34993673     DOI: 10.1007/s10388-021-00896-0

Source DB:  PubMed          Journal:  Esophagus        ISSN: 1612-9059            Impact factor:   4.230


  3 in total

1.  ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography for Evaluating the Response to Neoadjuvant Chemotherapy in Advanced Esophageal Cancer.

Authors:  Yukiko Tani; Masanobu Nakajima; Maiko Kikuchi; Keisuke Ihara; Hiroto Muroi; Masakazu Takahashi; Yasushi Domeki; Kentaro Okamoto; Satoru Yamaguchi; Kinro Sasaki; Takashi Tsuchioka; Setsu Sakamoto; Hiroyuki Kato
Journal:  Anticancer Res       Date:  2016-01       Impact factor: 2.480

2.  Prophylactic laparoscopic total gastrectomy for gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): the first report in Asia.

Authors:  Chihiro Matsumoto; Masaaki Iwatsuki; Shiro Iwagami; Takeshi Morinaga; Kohei Yamashita; Kenichi Nakamura; Kojiro Eto; Junji Kurashige; Yoshifumi Baba; Yuji Miyamoto; Naoya Yoshida; Yoshihiro Komohara; Hideo Baba
Journal:  Gastric Cancer       Date:  2021-09-23       Impact factor: 7.370

3.  Adverse Prognostic Factors of Advanced Esophageal Cancer in Patients Undergoing Induction Therapy with Docetaxel, Cisplatin and 5-Fluorouracil.

Authors:  Masanobu Nakajima; Hiroto Muroi; Maiko Kikuchi; Masakazu Takahashi; Keisuke Ihara; Yosuke Shida; Eigo Kurayama; Hideo Ogata; Satoru Yamaguchi; Kinro Sasaki; Makoto Sakai; Makoto Sohda; Tatsuya Miyazaki; Hiroyuki Kuwano; Hiroyuki Kato
Journal:  Anticancer Res       Date:  2018-02       Impact factor: 2.480

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.